Solid Tumor Antigens

Cat. No.

AT1489

CAS No.

2226224-30-0

Tinurilimab

Synonyms: BAY 1834942

Tinurilimab (Bay 1834942) is a monoclonal antibody targeting CEACAM6, a known immune checkpoint regulator that inhibits the activity of effector T-cells in tumor environments. This antibody is designed for the selective blockade of CEACAM6, facilitating the restoration of immune response against malignant cells. Tinurilimab is pivotal for research focused on immune checkpoint pathways and the development of therapeutic strategies in oncology.

Cat. No.

AT1520

Anti-TPBG Antibody

The Anti-TPBG Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the TPBG protein, making it a valuable tool for research into its biological functions and involvement in various cellular processes. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 145.8 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control is recommended.

Cat. No.

AT1523

CAS No.

1855925-27-7

Cibisatamab

Cibisatamab is a T cell bispecific antibody designed to simultaneously engage Carcino-Embryonic Antigen (CEA) present on the surface of cancer cells and the CD3 receptor on T cells. This dual binding capability facilitates the targeted destruction of cancer cells exhibiting moderate to high expression of CEA. Primarily utilized in the study of colorectal cancer, Cibisatamab is instrumental in advancing research focused on immune-mediated cancer cell eradication.

Cat. No.

AT1530

CAS No.

1622075-09-5

Clivatuzumab

Clivatuzumab is a humanized monoclonal antibody that specifically targets an epitope on the MUC1 antigen, which is predominantly expressed in pancreatic cancer cells. This antibody is designed to bind selectively to the MUC1 antigen, offering a targeted therapeutic approach predominantly used in the research and treatment of pancreatic cancer.

Cat. No.

AT1537

CAS No.

2867393-44-8

Omectatug

Omectatug is a humanized IgG1κ monoclonal antibody specifically targeting CLDN18. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

Cat. No.

AT1540

Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757)

The Anti-DLL3 Antibody is derived from the anti-DLL3 arm of Tarlatamab (AMG-757), a bispecific T-cell engager (BiTE) that simultaneously targets DLL3 on tumor cells and CD3 on T cells. This monoclonal antibody is designed for precision in targeting the Delta-like ligand 3 (DLL3) protein, a promising therapeutic target in neuroendocrine tumors, including small cell lung cancer. The antibody's specificity for DLL3 makes it an invaluable tool for research focused on cancer biology and the development of targeted cancer therapies.

Cat. No.

AT1543

Anti-DLL3 Antibody

Cat. No.

AT1549

MGD007

MGD007 is a humanized IgG1 monoclonal antibody that specifically targets GPA33, a cell surface antigen predominantly expressed in gastrointestinal tissues. This antibody is designed for the investigation of metastatic colorectal cancer, providing a critical tool for researchers studying the pathophysiology and potential therapeutic interventions for this disease. MGD007's specificity to GPA33 makes it an essential reagent for detailed cellular and molecular analysis in colorectal cancer research.

Cat. No.

AT1552

Anti-Ganglioside GD2 Antibody (14G2a)

Anti-Ganglioside GD2 Antibody (14G2a) is a chimeric mouse monoclonal antibody of the IgG2a, κ subtype, specifically designed to target human Ganglioside GD2. For accurate experimental control, it is recommended to use Mouse IgG2a kappa as the isotype control. This antibody is pivotal for studies focused on neuronal development, neuroblastoma, and other GD2-related pathologies.

Cat. No.

AT1553

CAS No.

2883771-43-3

Sonesitatug

Sonesitatug is a humanized IgG1κ monoclonal antibody that specifically targets CLDN18. For experimental rigor, it is recommended to use Human IgG1 kappa as an isotype control.